Ionis Pharmaceuticals, Inc. (LON:0JDI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.08B +124.1% |
| Revenue (ttm) | 801.37M +47.5% |
| Net Income | -247.62M |
| EPS | -1.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136 |
| Open | 74.63 |
| Previous Close | 75.40 |
| Day's Range | 74.63 - 76.31 |
| 52-Week Range | 34.14 - 86.72 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis Pharmaceuticals Transcript: AGM 2026
Accelerated transformation to a commercial-stage biotech has driven strong revenue growth and multiple independent product launches. A robust late-stage pipeline in cardiometabolic and neurology, combined with innovative RNA-targeted technologies, positions the company for over $7 billion in peak annual revenue and break-even cash flow by 2028.
Ionis Pharmaceuticals Slides: FY 2026
Ionis Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe...
Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced data for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B. Results from the two Phase 3 tria...
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for...
Ionis Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Significant pipeline progress includes two recent launches, multiple phase III readouts in 2026, and robust data for SHTG, tau, and rare neurology programs. Pricing and revenue guidance reflect strong demand, while market expansion is anticipated with new entrants. Key upcoming milestones include PDUFA dates and pivotal trial results.
Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi
Citi initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $115 price target and named it a top pick among small-to-mid cap biotech stocks. Tryngloza for severe hypertriglyceridemia...
Ionis Pharmaceuticals participates in a conference call with Cantor
Conference call with management will be held on May 15 at 11 am hosted by Cantor.Webcast Link
Ionis announces Biogen’s CELIA study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleoti...
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating dirane...
Ionis Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company reported robust commercial growth with INGREZZA, CRENESSITY, and VYKAT XR, and is advancing a broad pipeline with key phase III readouts expected in 2027–2028. Rare disease launches are driving rapid adoption, and the Soleno acquisition strengthens the rare endocrine portfolio.
Ionis to host 2026 virtual Annual Meeting of Stockholders
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corpora...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America ...
Ionis Pharmaceuticals price target raised to $111 from $104 at Oppenheimer
Oppenheimer raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $111 from $104 and keeps an Outperform rating on the shares. The firm notes the stock traded higher following…
Ionis Pharmaceuticals price target raised to $86 from $83 at Stifel
Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $83 and keeps a Hold rating on the shares.
Ionis Pharmaceuticals price target raised to $100 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $95 and keeps an Outperform rating on the shares. The firm cites the company’s better-than-expected Q1…
Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $125 from $120 and keeps a Buy rating on the shares. The firm says management commentary strengthens its…
Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
Barclays analyst Eliana Merle raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $115 from $106 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 87% revenue growth, driven by strong TRYNGOLZA and DAWNZERA launches and milestone payments. Guidance for 2026 was raised, with robust commercial and R&D revenue expected, and two major independent launches on track.
Ionis Pharmaceuticals Earnings release: Q1 2026
Ionis Pharmaceuticals released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Ionis Pharmaceuticals Slides: Q1 2026
Ionis Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Ionis Pharmaceuticals Quarterly report: Q1 2026
Ionis Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 29, 2026.
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)
Reports Q1 revenue $246M, consensus $196.01M. “Ionis’ strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasin...
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M
Consensus $811.3M. “Ionis entered 2026 with strong momentum. We continued this momentum with the first quarter financial results reflecting increased commercial revenue from our independent launches a...
Ionis reports first quarter 2026 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the first quarter ended March 31, 2026. “Ion...